Small Kidney Tumour: Do You Need Surgery, Biopsy or Just Active Surveillance?

A small kidney tumour is increasingly discovered incidentally during an ultrasound, CT scan or MRI performed for an entirely different reason.

The first reaction is understandably:

“There is a tumour in my kidney. Does it need to be removed immediately?”

Not necessarily.

Some small renal masses require surgery. Some benefit from a renal tumour biopsy before deciding treatment. And carefully selected tumours can be safely monitored through active surveillance.

The important point is that:

Finding a small kidney tumour does not automatically mean kidney cancer—and even when it is cancer, immediate surgery is not always necessary.

The appropriate decision depends on the tumour, the kidney and, importantly, the patient.

---

What Is a Small Renal Mass?

The term small renal mass (SRM) generally refers to a kidney tumour measuring 4 cm or less, corresponding to clinical stage T1a when confined to the kidney.

These tumours are commonly discovered incidentally.

A CT report may describe them using terms such as:

• Renal mass
• Enhancing renal lesion
• Solid renal lesion
• Cortical renal mass
• Suspicious renal lesion
• Small renal tumour

The word “mass” does not by itself mean cancer.

---

Are All Small Kidney Tumours Cancer?

No.

Although renal cell carcinoma is an important possibility, benign kidney tumours also occur.

The EAU guideline notes that approximately 15% of renal tumours are benign. Uroweb

Benign renal tumours include:

• Oncocytoma
• Angiomyolipoma
• Other less common benign lesions

Conversely, imaging alone cannot always reliably distinguish a benign tumour from renal cell carcinoma.

This creates an important clinical question:

Should every small renal mass automatically undergo surgery?

The answer is no.

---

The Three Main Options

For a patient with a small renal mass, management may broadly involve:

1. Surgery

Usually partial nephrectomy, when treatment is indicated and kidney preservation is technically feasible.

2. Renal tumour biopsy

Obtaining tissue from the tumour before deciding treatment in selected situations.

3. Active surveillance

Monitoring the tumour with scheduled imaging and intervening later if necessary.

These options are not interchangeable for every patient.

The decision should be individualised.

---

When Is Surgery Appropriate?

For a young or medically fit patient with a suspicious enhancing renal tumour and a long life expectancy, definitive treatment will often be appropriate.

When surgery is required for a localised T1 renal tumour, partial nephrectomy is generally preferred when technically feasible because it removes the tumour while preserving healthy functioning kidney.

Factors favouring active treatment may include:

• Larger tumour size
• Concerning radiological characteristics
• Demonstrated tumour growth
• Suspicion of aggressive biology
• Symptoms attributable to the tumour
• Long life expectancy
• Patient preference for definitive treatment

However, even when surgery is appropriate, removing the entire kidney is usually not automatically necessary for a small renal mass.

---

Why Partial Nephrectomy?

Partial nephrectomy removes the tumour while preserving the remaining kidney.

This is particularly relevant in patients with:

• Chronic kidney disease
• Solitary kidney
• Bilateral kidney tumours
• Diabetes
• Hypertension
• Proteinuria
• Conditions that may compromise future renal function

Partial nephrectomy can be performed through open, laparoscopic or robotic approaches depending upon tumour anatomy and surgical expertise.

For appropriately selected patients, robotic partial nephrectomy provides a minimally invasive approach to nephron-sparing surgery.

---

Does Every Small Kidney Tumour Need a Biopsy?

No.

This is another common misconception.

Unlike many other cancers, kidney tumours have traditionally often been treated surgically based on characteristic imaging findings without obtaining a biopsy first.

A renal tumour biopsy is particularly useful when the result is likely to change what we do next.

For example, biopsy may be useful when:

• Imaging is indeterminate
• Active surveillance is being considered
• Tumour ablation is planned
• The diagnosis may change management
• Histological information would help choose between surveillance and intervention

Current EAU guidance recommends renal tumour biopsy before ablative treatment and supports biopsy in selected patients considering active surveillance. Uroweb

---

How Is a Kidney Tumour Biopsy Performed?

A percutaneous renal mass biopsy is usually performed under ultrasound or CT guidance.

A needle is passed through the skin into the renal mass and tissue samples are obtained.

For solid renal tumours, core needle biopsy is generally preferred over fine-needle aspiration for histological characterisation. Uroweb

The procedure is typically performed using local anaesthesia with image guidance.

---

Is Kidney Tumour Biopsy Safe?

Modern percutaneous renal tumour biopsy is generally a low-morbidity procedure when appropriately performed.

Possible complications include:

• Bleeding
• Pain
• Haematoma
• Non-diagnostic sampling
• Very rare tumour seeding

The EAU recommends a coaxial biopsy technique, partly to minimise the risk of tumour seeding. Uroweb

The more practical limitation is often not safety but whether the biopsy will actually provide information that changes management.

---

Can a Biopsy Tell With Certainty Whether the Tumour Is Benign?

Not always.

Renal tumour biopsy has important limitations.

Occasionally, insufficient tissue is obtained and the biopsy is non-diagnostic.

Tumour heterogeneity can also complicate interpretation.

A particularly important example is oncocytoma. Under the current WHO classification, a definitive diagnosis of oncocytoma cannot always be established on core biopsy because some chromophobe renal cell carcinomas can contain areas that closely resemble oncocytoma. Uroweb

Therefore:

Biopsy is useful—but it is not infallible.

Its value depends upon the clinical question being asked.

---

When Is a Biopsy Not Necessary?

Consider a medically fit patient with a suspicious renal tumour for whom surgery has already been decided irrespective of the biopsy result.

If:

Biopsy says malignant → surgery

and

Biopsy is inconclusive → surgery

then obtaining a biopsy may not materially change management.

Current EAU guidance therefore states that renal tumour biopsy is not necessary in patients in whom surgery is already planned irrespective of the biopsy result. Uroweb

This is why the question should not simply be:

“Can we biopsy it?”

It should be:

“Will the biopsy result change the treatment decision?”

---

What Is Active Surveillance?

Active surveillance does not mean ignoring the tumour.

It is a structured management strategy in which the renal mass is monitored with serial imaging.

Treatment is deferred unless there is evidence that intervention has become appropriate.

Monitoring may involve:

• Ultrasound
• CT
• MRI
• Clinical assessment
• Renal function assessment

The purpose is to avoid or delay treatment in patients whose tumour may never cause clinically meaningful harm while retaining the option of intervention if the tumour changes.

EAU defines active surveillance as serial imaging of tumour size with delayed intervention reserved for tumours showing clinical progression. Uroweb

---

Is Active Surveillance Safe?

For appropriately selected small renal masses, active surveillance can be a reasonable strategy.

Most small renal masses under surveillance demonstrate relatively slow growth, although behaviour varies between tumours.

Across active-surveillance cohorts, progression to metastatic disease has been uncommon, reported at approximately 1–2%. Uroweb

This does not mean every small kidney cancer should simply be watched.

It means that immediate treatment is not necessarily required for every patient with every small renal mass.

---

Who May Be Suitable for Active Surveillance?

Active surveillance may be particularly relevant for:

• Older patients
• Frail patients
• Patients with significant medical comorbidities
• Patients in whom surgery carries substantial risk
• Very small renal masses
• Patients with competing health risks
• Selected patients who wish to defer treatment after appropriate counselling

The AUA guideline specifically states that active surveillance may be elected as initial management for a solid renal mass smaller than 2 cm or a complex but predominantly cystic mass. American Urological Association

Current EAU guidance also supports active surveillance for selected cT1a tumours where there is no indication for immediate treatment and delayed intervention may be appropriate. Uroweb

---

Does Active Surveillance Mean the Cancer Is Being Left Untreated?

This terminology can understandably worry patients.

But active surveillance is itself a management strategy.

The tumour is deliberately monitored so that intervention can be performed if its behaviour changes.

This is fundamentally different from watchful waiting.

Active surveillance

The tumour is regularly monitored and delayed curative treatment remains an option.

Watchful waiting

This is generally used when a patient's frailty, comorbidities or limited life expectancy mean that definitive treatment is unlikely to provide meaningful benefit. Management is directed primarily towards symptoms rather than planned future curative intervention.

The distinction is important. Uroweb

---

How Often Is the Tumour Scanned?

There is no single surveillance schedule appropriate for every patient.

For patients choosing active surveillance when the balance between intervention and surveillance remains uncertain, AUA guidance suggests repeat cross-sectional imaging at approximately 3–6 months initially to assess interval growth, followed by surveillance tailored according to growth and shared decision-making. American Urological Association

Subsequent imaging depends upon:

• Initial tumour size
• Growth
• Imaging characteristics
• Biopsy findings when available
• Patient age
• Medical fitness
• Kidney function
• Overall treatment strategy

---

What Makes Us Change From Surveillance to Treatment?

A tumour being monitored today does not mean it must remain under surveillance forever.

Treatment may subsequently be considered if there is:

• Meaningful interval growth
• Increasing tumour size
• Development of concerning radiological characteristics
• Concerning biopsy findings
• Symptoms
• Change in patient preference
• Change in the balance between treatment benefit and risk

Therefore, active surveillance retains the possibility of delayed intervention.

---

Does Tumour Growth Automatically Mean Cancer?

No.

Growth alone does not establish histology.

Some benign renal tumours grow, while some malignant renal tumours grow very slowly.

Similarly, absence of growth over a short period does not prove that a tumour is benign.

This is why management should integrate:

Imaging + growth pattern + patient characteristics + biopsy when useful + clinical judgement

rather than relying on one parameter alone.

---

What About a 1–2 cm Kidney Tumour?

Very small renal masses deserve particularly thoughtful decision-making.

A 1.5 cm enhancing renal lesion in an otherwise healthy 40-year-old patient is a very different clinical situation from the same lesion in an 85-year-old patient with severe cardiac and pulmonary disease.

The scan may look identical.

The appropriate treatment may not be.

This illustrates an important principle in uro-oncology:

We treat the patient and the tumour—not the CT scan alone.

---

Does Age Alone Decide Treatment?

No.

Chronological age should not be considered in isolation.

An active 78-year-old with few medical problems may have a very different treatment strategy from a frail 68-year-old with major cardiovascular, respiratory and renal disease.

Important considerations include:

• Physiological fitness
• Life expectancy
• Comorbidities
• Baseline renal function
• Surgical risk
• Tumour characteristics
• Patient priorities

The decision should therefore be individualised.

---

What About Cryoablation or Other Ablative Treatments?

Surgery, biopsy and surveillance are not the only possibilities.

Selected small renal tumours may be treated using tumour ablation, including techniques such as cryoablation.

These treatments may be particularly relevant for selected patients who require treatment but are poor candidates for surgery.

However, current evidence suggests that local recurrence may be higher after some ablative approaches than after partial nephrectomy, and patient selection is important. EAU guidance recommends obtaining a renal tumour biopsy before tumour ablation. Uroweb

Ablation deserves a separate discussion and will be covered in another article in this series.

---

Surgery vs Biopsy vs Surveillance: How Do We Decide?

There is no single tumour-size cut-off that provides the complete answer.

The decision should consider three broad areas.

The tumour

• Size
• Enhancement pattern
• Solid versus cystic
• Growth
• Location
• Anatomical complexity
• Suspicion of aggressive disease

The kidney

• Baseline kidney function
• Condition of the opposite kidney
• Solitary kidney
• Bilateral tumours
• Existing chronic kidney disease

The patient

• Age
• Overall fitness
• Diabetes
• Hypertension
• Cardiovascular disease
• Other cancers or serious illnesses
• Life expectancy
• Patient preference

Only after combining these factors can an appropriate management strategy be developed.

---

A Practical Example

Consider three patients who each have a 2 cm enhancing kidney tumour.

Patient A

45 years old, medically fit, normal renal function and a suspicious solid renal tumour.

Definitive treatment—often nephron-sparing surgery—may be appropriate.

Patient B

72 years old with moderate comorbidity and an indeterminate renal mass.

A renal tumour biopsy may provide information that meaningfully influences whether treatment or surveillance is preferable.

Patient C

86 years old with severe cardiac disease and multiple competing medical risks.

Active surveillance or conservative management may provide a more appropriate balance than immediate surgery.

The tumour diameter is identical.

The correct clinical decision may be completely different.

---

Small Kidney Tumour Evaluation in Lucknow

At Uro-Onco Connect, Lucknow, assessment of a small renal mass focuses first on establishing whether immediate treatment is actually necessary.

Evaluation may include:

Review of CT/MRI → tumour characterisation → kidney function → tumour complexity → patient fitness → role of renal tumour biopsy → active surveillance versus intervention → partial versus radical nephrectomy → robotic surgery where appropriate

The objective is to avoid both extremes:

Unnecessary treatment of every small renal mass

and

Inappropriate delay in treating a tumour that requires intervention.

For patients requiring surgery, kidney preservation through partial nephrectomy or robotic partial nephrectomy is considered whenever oncologically and technically appropriate.

---

The Key Message

A small kidney tumour does not automatically mean:

Cancer → immediate surgery → removal of the whole kidney.

Modern management is considerably more individualised.

Depending upon the circumstances, the appropriate pathway may be:

Small renal mass → careful imaging assessment → biopsy when it can change management → active surveillance for selected patients → kidney-preserving surgery when treatment is required.

The most important step is therefore not rushing to a particular treatment.

It is establishing what the tumour is likely to represent, how it is behaving, what risk it poses to the individual patient and whether treatment now provides more benefit than careful surveillance.

---

About Dr. Anshuman Singh

Dr. Anshuman Singh
M.S., M.Ch. Urology (Gold Medalist)
Fellowship – Uro-Oncology & Robotic Surgery (USI, Intuitive Certified)
Visiting Fellow – Robotic Uro-Oncology (Fundació Puigvert, Spain)
Clinical Observer – Robotic Pelvic Oncology (University College Hospitals, London)

Vice Chairperson – Uro-Oncology & Robotic Surgery
Chandan Cancer Institute, Chandan Hospital
Lucknow

Dr. Anshuman Singh's clinical practice focuses on Uro-Oncology and Robotic Surgery, including kidney, prostate, bladder, testicular and penile cancers.

Patients diagnosed with a small renal mass or kidney tumour can seek specialist evaluation regarding renal tumour biopsy, active surveillance, partial nephrectomy, robotic partial nephrectomy and other kidney cancer treatment options.

References

1. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Diagnostic Evaluation. 2026. Uroweb
2. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: Disease Management. 2026. Uroweb
3. American Urological Association. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up Guideline. 2021. American Urological Association
4. Pierorazio PM, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM Registry. Eur Urol. 2015;68:408–415. Uroweb
5. Finelli A, et al. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. Eur Urol. 2020;78:460–467.